Patent: 9,499,850
✉ Email this page to a colleague
Summary for Patent: 9,499,850
Title: | Modified influenza virus for monitoring and improving vaccine efficiency |
Abstract: | The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines. |
Inventor(s): | Hoffmann; Erich (Galveston, TX), Lipatov; Aleksandr S. (Atlanta, GA), Webby; Richard J. (Memphis, TN), Govorkova; Elena A. (Cordova, TN), Webster; Robert G. (Memphis, TN) |
Assignee: | St. Jude Children\'s Research Hospital (Memphis, TN) |
Application Number: | 14/045,097 |
Patent Claims: | see list of patent claims |
Details for Patent 9,499,850
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Seqirus Vaccines Limited | FLUVIRIN | influenza virus vaccine | Injection | 103837 | 11/03/1998 | ⤷ Try a Trial | 2025-08-04 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 12/09/1999 | ⤷ Try a Trial | 2025-08-04 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 12/23/1909 | ⤷ Try a Trial | 2025-08-04 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 05/09/2011 | ⤷ Try a Trial | 2025-08-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |